Browse by category

The last participant has been randomised and dosed in Amylyx Pharmaceuticals’ pivotal Phase 3 LUCIDITY clinical trial of avexitide, an investigational, first-in-class glucagon-like peptide-1 (GLP-1) receptor antagonist with an FDA Breakthrough Therapy Designation in post-bariatric hypoglycemia (PBH). LUCIDITY is a 16-week, multicentre, randomised, double-blind, placebo-controlled trial evaluating the efficacy and safety of avexitide in adults with PBH following Roux-en-Y gast

Both Roux-en-Y gastric bypass (RYGB) and single-anastomosis duodeno-ileal bypass (SADI-S) are effective and safe revisional options after sleeve gastrectomy (SG), according to researchers from Hamad Medical Corporation, Doha, Qatar. They noted that SADI-S offers superior long-term weight-loss and metabolic outcomes, whereas RYGB remains preferable for patients with significant or persistent GERD. “Tailoring revisional procedure selection to patient characteristics and ensurin

Researchers from Saudi Arabia have reported that although general awareness of obesity’s metabolic impact is high, understanding of the therapeutic role of metabolic bariatric surgery for T2DM remained limited. Despite that fact that injectable therapies were more frequently preferred than surgical options, their study did not find definitive conclusions regarding the underlying drivers of these preferences. “These findings highlight the need for structured public education i

Researchers from Northwestern Medicine at Northwestern University, Chicago, Ill, have discovered novel molecular mechanisms that contribute to recovery from diabetic kidney disease following bariatric surgery in adolescents with type 2 diabetes and obesity. These mechanisms may serve as potential targets for non-surgical treatments for diabetic kidney disease, according to a multi-institutional study co-authored by Dr Thomas Inge, the Lydia J Fredrickson Board Designated Prof

Marginal ulcers (MU) occurred at a relatively high rate after Roux-en-Y gastric bypass (RYGB) compared with one-anastomosis gastric bypass (OAGB), according to a study by researchers from the Kasr Alainy Medical School, Cairo University, Cairo, Egypt. They noted that type 2 diabetes mellitus (T2DM) and the RYGB procedure were significant predictors of MU after adjusting for the confounding factors. The authors noted that despite the success of RYGB, MU has been recognised as

GLP-1 medications used to treat diabetes and obesity were associated with a reduced need for hospital care and sickness absence due to psychiatric reasons, according to a large register-based study carried out in collaboration between the University of Eastern Finland, Karolinska Institutet in Stockholm and Griffith University in Australia. Infographic on anxiety and depression in the UK (Credit: Mark Taylor) "An earlier study examining Swedish registers found the use of GLP-